Evidence map›Paper›PMID 31769415›Full record

ArticleCancers2019

The Role of 18F-FDG PET/CT in Staging and Prognostication of Mantle Cell Lymphoma: An Italian Multicentric Study.

Domenico Albano, Riccardo Laudicella, Paola Ferro, Michela Allocca, Elisabetta Abenavoli, Ambra Buschiazzo, Alessia Castellino, Agostino Chiaravalloti, Annarosa Cuccaro, Lea Cuppari and 9 more

Abstract read
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Domenico AlbanoNuclear Medicine, University of Brescia, Spedali Civili Brescia, 25123 Brescia, Italy.ORCID 0000-0003-0810-6494
Riccardo LaudicellaNuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, 98125 Messina, Italy.ORCID 0000-0002-2842-0301
Paola FerroNuclear Medicine Department, IRCCS San Raffaele Hospital, 20132 Milan, Italy.
Michela AlloccaNuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50134 Florence, Italy.
Elisabetta AbenavoliNuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50134 Florence, Italy.
Ambra BuschiazzoNuclear Medicine Department, S. Croce e Carle Hospital Cuneo, 12100 Cuneo, Italy.
Alessia CastellinoHematology Division, S. Croce e Carle Hospital Cuneo, 12100 Cuneo, Italy.
Agostino ChiaravallotiDepartment of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-8017-8858
Annarosa CuccaroIstituto di Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Lea CuppariNuclear Medicine and Molecular Imaging Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.ORCID 0000-0002-5277-6105
Rexhep DurmoNuclear Medicine, University of Brescia, Spedali Civili Brescia, 25123 Brescia, Italy.ORCID 0000-0001-9210-666X
Laura EvangelistaNuclear Medicine Unit, Department of Medicine - DIMED, University of Padua, 35121 Padua, Italy.ORCID 0000-0002-5955-9488
Viviana FrantellizziDepartment of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0003-3497-4236
Sofya KovalchukHematology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50134 Florence, Italy.
Flavia LinguantiNuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50134 Florence, Italy.
Giulia SantoNuclear Medicine Unit, Department of Interdisciplinary Medicine, University of Bari Aldo Moro, 70124 Bari, Italy.
Matteo BaucknehtNuclear Medicine, IRCCS Policlinico San Martino, 16132 Genova, Italy.ORCID 0000-0002-1937-9116
Salvatore AnnunziataInstitute of Nuclear Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Young Italian Association of Nuclear Medicine

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mantle cell lymphoma (MCL) is an aggressive lymphoma subtype with poor prognosis in which 18F-FDG-PET/CT role in treatment response evaluation and prediction of outcome is still unclear. The aim of this multicentric study was to investigate the role of 18F-FDG-PET/CT in staging MCL and the prognostic role of Deauville criteria (DC) in terms of progression-free survival (PFS) and overall survival (OS). We retrospectively enrolled 229 patients who underwent baseline and end-of-treatment (eot) 18F-FDG-PET/CT after first-line therapy. EotPET/CT scans were visually interpreted according to DC. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of PET/CT for evaluation of bone marrow (BM) were 27%, 100%, 100%, 48% and 57%, respectively. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of PET/CT for evaluation of the gastrointestinal (GI) tract were 60%, 99%, 93%, 90% and 91%, respectively. At a median follow-up of 40 months, relapse occurred in 104 cases and death in 49. EotPET/CT results using DC significantly correlated with PFS, not with OS. Instead, considering OS, only MIPI score was significantly correlated. In conclusion, we demonstrated that MCL is an FDG-avid lymphoma and 18F-FDG-PET/CT is a useful tool for staging purpose, showing good specificity for BM and GI evaluation, but suboptimal sensitivity. EotPET/CT result was the only independent significant prognostic factor that correlated with PFS.

Indexed as

18F-FDG PET/CTDeauville criteriamantle cell lymphomaprognosis

Identifiers

PMID31769415
PMCPMC6966583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.